US6652882B1
(en)
*
|
1997-10-06 |
2003-11-25 |
Intellipharmaceutics Corp |
Controlled release formulation containing bupropion
|
US5968553A
(en)
*
|
1997-12-30 |
1999-10-19 |
American Home Products Corporation |
Pharmaceutical composition containing bupropion hydrochloride and an inorganic acid stabilizer
|
US6221917B1
(en)
*
|
1997-12-30 |
2001-04-24 |
American Home Products Corporation |
Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
|
US7098206B2
(en)
*
|
1998-01-21 |
2006-08-29 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US6998400B2
(en)
*
|
1998-01-22 |
2006-02-14 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US6110973A
(en)
*
|
1998-01-29 |
2000-08-29 |
Sepracor |
Methods for treating obesity and weight gain using optically pure (-)-bupropion
|
CA2318921A1
(en)
|
1998-01-29 |
1999-08-05 |
John R. Mccullough |
Pharmacological uses of optically pure (+)-bupropion
|
AU2483499A
(en)
*
|
1998-01-29 |
1999-08-16 |
Sepracor, Inc. |
Pharmaceutical uses of optically pure (+)-bupropion
|
US6153223A
(en)
*
|
1998-06-05 |
2000-11-28 |
Watson Pharmaceuticals, Inc. |
Stabilized pharmaceutical compositions
|
CN1331576A
(zh)
*
|
1998-06-29 |
2002-01-16 |
药品应用协会有限公司 |
用于缓解疼痛的方法和经皮组合物
|
US6238697B1
(en)
*
|
1998-12-21 |
2001-05-29 |
Pharmalogix, Inc. |
Methods and formulations for making bupropion hydrochloride tablets using direct compression
|
US6734213B2
(en)
|
1999-01-20 |
2004-05-11 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US6855820B2
(en)
*
|
1999-01-20 |
2005-02-15 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US6210716B1
(en)
|
1999-02-26 |
2001-04-03 |
Andrx Pharmaceuticals, Inc. |
Controlled release bupropion formulation
|
US8545880B2
(en)
*
|
1999-02-26 |
2013-10-01 |
Andrx Pharmaceuticals, Llc |
Controlled release oral dosage form
|
US6342496B1
(en)
|
1999-03-01 |
2002-01-29 |
Sepracor Inc. |
Bupropion metabolites and methods of use
|
US6337328B1
(en)
|
1999-03-01 |
2002-01-08 |
Sepracor, Inc. |
Bupropion metabolites and methods of use
|
US6280763B1
(en)
|
1999-05-10 |
2001-08-28 |
Pierce Management, Llc |
Apparatus and method for transdermal delivery of bupropion
|
US6312716B1
(en)
*
|
1999-05-10 |
2001-11-06 |
Peierce Management Llc |
Patch and method for transdermal delivery of bupropion base
|
WO2001078721A1
(en)
*
|
2000-04-13 |
2001-10-25 |
Mayo Foundation For Medical Education And Research |
Aβ42 LOWERING AGENTS
|
US6306436B1
(en)
|
2000-04-28 |
2001-10-23 |
Teva Pharmaceuticals Usa, Inc. |
Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
|
US6333332B1
(en)
*
|
2000-08-25 |
2001-12-25 |
Impax Laboratories, Inc. |
Stabilized pharmaceutical compositions containing bupropion hydrochloride
|
US20030044462A1
(en)
*
|
2001-08-20 |
2003-03-06 |
Kali Laboratories, Inc. |
Sustained release tablets containing bupropion hydrochloride
|
EP2266590A3
(en)
|
2002-02-22 |
2011-04-20 |
Shire LLC |
Active agent delivery sytems and methods for protecting and administering active agents
|
EP1505967B1
(en)
*
|
2002-05-17 |
2016-07-13 |
Duke University |
Method for treating obesity
|
US20050215552A1
(en)
*
|
2002-05-17 |
2005-09-29 |
Gadde Kishore M |
Method for treating obesity
|
US6893660B2
(en)
*
|
2002-11-21 |
2005-05-17 |
Andrx Pharmaceuticals, Inc. |
Stable pharmaceutical compositions without a stabilizer
|
WO2004071431A2
(en)
*
|
2003-02-05 |
2004-08-26 |
Myriad Genetics, Inc. |
Method and composition for treating neurodegenerative disorders
|
US20040191298A1
(en)
*
|
2003-03-26 |
2004-09-30 |
Fredrik Nicklasson |
New formulations and use thereof
|
ES2303085T3
(es)
|
2003-04-29 |
2008-08-01 |
Orexigen Therapeutics, Inc. |
Composiciones que afectan a la perdida de peso.
|
WO2005065069A2
(en)
*
|
2003-07-11 |
2005-07-21 |
Myriad Genetics, Inc. |
Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
|
US20050096311A1
(en)
*
|
2003-10-30 |
2005-05-05 |
Cns Response |
Compositions and methods for treatment of nervous system disorders
|
BRPI0506829A
(pt)
|
2004-01-13 |
2007-05-29 |
Univ Duke |
composições de anticonvulsivo e droga antipsicótica e métodos para sua utilização para afetar perda de peso
|
US20060160750A1
(en)
*
|
2004-01-13 |
2006-07-20 |
Krishnan K R R |
Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
|
US7713959B2
(en)
*
|
2004-01-13 |
2010-05-11 |
Duke University |
Compositions of an anticonvulsant and mirtazapine to prevent weight gain
|
US20070293538A1
(en)
*
|
2004-04-13 |
2007-12-20 |
Myriad Genetics, Incorporated |
Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
|
US20060100205A1
(en)
*
|
2004-04-21 |
2006-05-11 |
Eckard Weber |
Compositions for affecting weight loss
|
CN1946906A
(zh)
*
|
2004-04-29 |
2007-04-11 |
吉斯通护岸系统股份有限公司 |
用于墙、护墙和类似物的饰面
|
WO2006020850A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
WO2006020852A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
CA2618985A1
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
US20060099262A1
(en)
*
|
2004-11-08 |
2006-05-11 |
Biokey, Inc. |
Methods and formulations for making controlled release oral dosage form
|
US8586085B2
(en)
*
|
2004-11-08 |
2013-11-19 |
Biokey, Inc. |
Methods and formulations for making pharmaceutical compositions containing bupropion
|
KR100670798B1
(ko)
|
2004-12-17 |
2007-01-17 |
한국전자통신연구원 |
데이터베이스 캐시 시스템
|
US20060204571A1
(en)
*
|
2005-03-12 |
2006-09-14 |
Sun Pharmaceutical Industries Limited |
Stable compositions of bupropion or its pharmaceutically acceptable salts
|
CA2578626C
(en)
|
2005-06-27 |
2011-07-19 |
Biovail Laboratories International S.R.L. |
Modified-release formulations of a bupropion salt
|
NZ564789A
(en)
*
|
2005-07-22 |
2010-07-30 |
Myriad Genetics Inc |
High drug load formulations and dosage forms
|
CA2625835A1
(en)
*
|
2005-10-14 |
2007-05-10 |
Forest Laboratories, Inc. |
Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
|
JP2009511607A
(ja)
*
|
2005-10-14 |
2009-03-19 |
ハー・ルンドベック・アクチエゼルスカベット |
エスシタロプラムおよびブプロピオンを含有する安定な医薬製剤
|
ES2761812T3
(es)
|
2005-11-22 |
2020-05-21 |
Nalpropion Pharmaceuticals Inc |
Composición y métodos de aumento de la sensibilidad a la insulina
|
AR057946A1
(es)
*
|
2005-11-28 |
2007-12-26 |
Orexigen Therapeutics Inc |
Formulacion de zonisamida de liberacion sostenidda
|
WO2007101224A2
(en)
*
|
2006-02-27 |
2007-09-07 |
The Board Of Trustees Of The Leland Stanford Junior University |
Inhibitors of the unfolded protein response and methods for their use
|
US8916195B2
(en)
|
2006-06-05 |
2014-12-23 |
Orexigen Therapeutics, Inc. |
Sustained release formulation of naltrexone
|
KR20090029725A
(ko)
|
2006-06-13 |
2009-03-23 |
더 보드 오브 트러스티즈 오프 더 리랜드 스탠포드 쥬니어 유니버시티 |
시스테인 프로테아제의 에폭시드 저해물질
|
EP2046119A2
(en)
*
|
2006-07-07 |
2009-04-15 |
Myriad Genetics, Inc. |
Treatment of psychiatric disorders
|
US7674479B2
(en)
*
|
2006-07-25 |
2010-03-09 |
Intelgenx Corp. |
Sustained-release bupropion and bupropion/mecamylamine tablets
|
US8703191B2
(en)
*
|
2006-07-25 |
2014-04-22 |
Intelgenx Corp. |
Controlled-release pharmaceutical tablets
|
KR100843021B1
(ko)
*
|
2006-09-11 |
2008-07-01 |
주식회사 드림파마 |
안정성이 개선된 디에틸프로피온 하이드로클로라이드를포함하는 경구투여용 고형 제제
|
JP2010509367A
(ja)
|
2006-11-09 |
2010-03-25 |
オレキシジェン・セラピューティクス・インコーポレーテッド |
積層製剤
|
KR20090090316A
(ko)
*
|
2006-11-09 |
2009-08-25 |
오렉시젠 세러퓨틱스 인크. |
체중 감량 약물을 투여하기 위한 단위 용량 팩키지 및 투여 방법
|
KR20100015923A
(ko)
|
2007-04-09 |
2010-02-12 |
세프라코 아이엔시. |
수면관련 호흡 장애를 치료하는 방법들 및 수면관련 호흡 장애 치료용 조성물들
|
US9339500B2
(en)
*
|
2008-03-04 |
2016-05-17 |
Intra-Cellular Therapies, Inc. |
Methods of treating vasomotor symptoms
|
WO2009158114A1
(en)
|
2008-05-30 |
2009-12-30 |
Orexigen Therapeutics, Inc. |
Methods for treating visceral fat conditions
|
TW201039815A
(en)
|
2009-04-13 |
2010-11-16 |
Resolvyx Pharmaceuticals Inc |
Compositions and methods for the treatment of inflammation
|
US20110136815A1
(en)
*
|
2009-12-08 |
2011-06-09 |
Horst Zerbe |
Solid oral film dosage forms and methods for making same
|
US10610528B2
(en)
|
2009-12-08 |
2020-04-07 |
Intelgenx Corp. |
Solid oral film dosage forms and methods for making same
|
JP6196041B2
(ja)
|
2010-01-11 |
2017-09-13 |
オレキシジェン・セラピューティクス・インコーポレーテッド |
大うつ病を有する患者において減量療法を提供する方法
|
WO2012051117A2
(en)
|
2010-10-11 |
2012-04-19 |
The Board Of Trustees Of The Leland Stanford Junior University |
Substituted benzamides and their uses
|
KR101534606B1
(ko)
*
|
2011-11-08 |
2015-07-10 |
알보젠코리아 주식회사 |
사포그릴레이트의 안정화된 지속 방출 제제
|
EA201692166A1
(ru)
|
2011-11-21 |
2017-07-31 |
Калитера Байосайенсиз Инк. |
Гетероциклические ингибиторы глютаминазы
|
RU2014141510A
(ru)
|
2012-04-12 |
2016-06-10 |
Дзе Борд Оф Трастиз Оф Дзе Лелэнд Стэнфорд Джуниор Юниверсити |
Замещенные бензамиды и их применения, перекрестная ссылка на связанные заявки
|
BR112014030282A2
(pt)
|
2012-06-06 |
2017-06-27 |
Orexigen Therapeutics Inc |
métodos de tratamento de excesso de peso e obesidade
|
MX2015005963A
(es)
|
2012-11-16 |
2015-09-16 |
Calithera Biosciences Inc |
Inhibidores heterociclicos de glutaminasa.
|
CN105431546A
(zh)
|
2013-03-15 |
2016-03-23 |
里兰斯坦福初级大学理事会 |
基于活性的探针化合物、组合物及其使用方法
|
US11324670B2
(en)
*
|
2013-10-16 |
2022-05-10 |
Bilal Walk |
Cocoa butter powdered moisturizer
|
US11969421B2
(en)
|
2013-11-05 |
2024-04-30 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
CA2952213A1
(en)
|
2014-06-13 |
2015-12-17 |
Calithera Biosciences, Inc. |
Combination therapy with glutaminase inhibitors
|
AU2015300825B2
(en)
|
2014-08-07 |
2019-10-10 |
Calithera Biosciences, Inc. |
Crystal forms of glutaminase inhibitors
|
US10221170B2
(en)
|
2014-08-13 |
2019-03-05 |
Eolas Therapeutics, Inc. |
Difluoropyrrolidines as orexin receptor modulators
|
WO2016070063A1
(en)
|
2014-10-31 |
2016-05-06 |
The Regents Of The University Of California |
Compositions and methods for treating hiv-associated cognitive dysfunction
|
KR101612197B1
(ko)
*
|
2014-11-25 |
2016-04-14 |
알보젠코리아 주식회사 |
부프로피온 염산염을 함유하는 안정화된 정제 및 이의 제조방법
|
SG11201706908PA
(en)
|
2015-03-10 |
2017-09-28 |
Aurigene Discovery Tech Ltd |
1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
|
EP3313410A4
(en)
|
2015-06-23 |
2019-01-02 |
Calithera Biosciences, Inc. |
Compositions and methods for inhibiting arginase activity
|
GB2542881B
(en)
|
2015-10-02 |
2020-01-01 |
Carr Andrew |
Crystal forms of ß-nicotinamide mononucleotide
|
SG11201802830QA
(en)
|
2015-10-05 |
2018-05-30 |
Calithera Biosciences Inc |
Combination therapy with glutaminase inhibitors and immuno-oncology agents
|
WO2017075363A1
(en)
|
2015-10-30 |
2017-05-04 |
Calithera Biosciences, Inc. |
Compositions and methods for inhibiting arginase activity
|
EP3377512A4
(en)
|
2015-11-16 |
2019-09-18 |
Ichorion Therapeutics, Inc. |
NUCLEIC ACID PRODRUGS
|
SG11201806368VA
(en)
|
2016-02-12 |
2018-08-30 |
Astrazeneca Ab |
Halo-substituted piperidines as orexin receptor modulators
|
US10793590B2
(en)
|
2016-06-03 |
2020-10-06 |
President And Fellows Of Harvard College |
Antifungal compounds
|
WO2018039612A1
(en)
|
2016-08-26 |
2018-03-01 |
The Regents Of The University Of California |
Compositions and methods for promoting hair growth with mpc1 inhibitors
|
CN110234656B
(zh)
|
2016-09-09 |
2023-02-28 |
卡利泰拉生物科技公司 |
外核苷酸酶抑制剂及其使用方法
|
WO2018049094A1
(en)
|
2016-09-09 |
2018-03-15 |
The Regents Of The University Of California |
Estrogen receptor ligands, compositions and methods related thereto
|
JP7203018B2
(ja)
|
2016-09-26 |
2023-01-12 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
クロモボックスタンパク質阻害剤およびその使用
|
CN110290835B
(zh)
|
2016-09-28 |
2023-03-07 |
麦迪康制药公司 |
用于治疗眼科病况的组合物和方法
|
JP7030345B2
(ja)
|
2016-09-28 |
2022-03-07 |
メディコン ファーマシューティカルズ,インコーポレイテッド |
眼の状態を処置する組成物および方法
|
KR20190104521A
(ko)
|
2016-11-08 |
2019-09-10 |
칼리테라 바이오사이언시즈, 인코포레이티드 |
아르기나제 억제제 병용 요법들
|
RS61996B1
(sr)
|
2016-12-22 |
2021-07-30 |
Calithera Biosciences Inc |
Kompozicije i postupci za inhibiranje aktivnosti arginaze
|
CN116217656A
(zh)
|
2016-12-23 |
2023-06-06 |
里兰斯坦福初级大学理事会 |
基于活性的探针化合物、组合物及其使用方法
|
JP2020511424A
(ja)
|
2017-01-18 |
2020-04-16 |
ヴァンダービルト ユニバーシティーVanderbilt University |
選択的bmp阻害としての縮合複素環式化合物
|
JP7146785B2
(ja)
|
2017-02-24 |
2022-10-04 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ジヒドロオロテートオキシゲナーゼ阻害剤としての1、4、6-トリ置換-2-アルキル-1H-ベンゾ[d]イミダゾール誘導体
|
IL269536B
(en)
|
2017-03-31 |
2022-07-01 |
Aurigene Discovery Tech Ltd |
Compounds and preparations for the treatment of hematological disorders
|
US10994025B2
(en)
|
2017-05-12 |
2021-05-04 |
Massachusetts Institute Of Technology |
Argonaute protein-double stranded RNA complexes and uses related thereto
|
WO2018223032A1
(en)
|
2017-06-02 |
2018-12-06 |
Stealth Biotherapeutics Corp. |
Crystalline salt forms of sbt-20
|
KR102642823B1
(ko)
|
2017-06-30 |
2024-03-04 |
더 리전트 오브 더 유니버시티 오브 캘리포니아 |
모발 성장을 조절하기 위한 조성물 및 방법
|
WO2019018539A1
(en)
|
2017-07-19 |
2019-01-24 |
California Institute Of Technology |
PROCESSES FOR PREPARING COMPOUNDS CONTAINING BIS-TETRAHYDROISOQUINOLINE
|
EA202090536A1
(ru)
|
2017-10-11 |
2020-07-22 |
Ориджен Дискавери Текнолоджис Лимитед |
Кристаллические формы 3-замещенного 1,2,4-оксадиазола
|
KR102697663B1
(ko)
|
2017-10-31 |
2024-08-21 |
쿠리스 인코퍼레이션 |
혈액학적 장애를 치료하기 위한 화합물 및 조성물
|
SG11202003625VA
(en)
|
2017-11-03 |
2020-05-28 |
Aurigene Discovery Tech Ltd |
Dual inhibitors of tim-3 and pd-1 pathways
|
WO2019087092A1
(en)
|
2017-11-06 |
2019-05-09 |
Aurigene Discovery Technologies Limited |
Conjoint therapies for immunomodulation
|
CA3085097A1
(en)
|
2017-12-22 |
2019-06-27 |
Medimmune Limited |
Small molecule modulators of the btb domain of keap1
|
EP3765460A1
(en)
|
2018-03-14 |
2021-01-20 |
Vanderbilt University |
Inhibition of bmp signaling, compounds, compositions and uses thereof
|
US10933084B2
(en)
|
2018-04-12 |
2021-03-02 |
MatRx Therapeutics Corporation |
Compositions and methods for treating elastic fiber breakdown
|
WO2019217450A1
(en)
|
2018-05-08 |
2019-11-14 |
Rhode Island Hospital |
Anti-chi3l1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatohepatitis and subsequent complications
|
EP3813841A4
(en)
|
2018-06-29 |
2022-03-09 |
The Regents Of The University Of California |
NEW MOLECULAR FORCEPS AGAINST NEUROLOGICAL DISORDERS AND VIRAL INFECTION
|
EP3830082A4
(en)
|
2018-07-27 |
2022-05-11 |
California Institute of Technology |
CDK INHIBITORS AND USES THEREOF
|
JP2021535181A
(ja)
|
2018-09-05 |
2021-12-16 |
ザ ジェネラル ホスピタル コーポレイション |
サイトカイン放出症候群を処置する方法
|
CA3117695A1
(en)
|
2018-10-26 |
2020-04-30 |
Keros Therapeutics, Inc. |
Crystal forms of an alk2 inhibitor
|
US11248001B2
(en)
|
2019-01-18 |
2022-02-15 |
Astrazeneca Ab |
PCSK9 inhibitors and methods of use thereof
|
CA3125991A1
(en)
|
2019-01-25 |
2020-07-30 |
Brown University |
Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
|
JP2022523510A
(ja)
|
2019-01-31 |
2022-04-25 |
エレクトロフィ,インコーポレイテッド |
粒子形成及び形態構造
|
WO2020183021A1
(en)
|
2019-03-14 |
2020-09-17 |
Astrazeneca Ab |
Lanabecestat for weight loss
|
CN113874375A
(zh)
|
2019-06-03 |
2021-12-31 |
株式会社大分大学先端医学研究所 |
用于治疗狂犬病的环状酰胺化合物及其方法
|
CN110200947A
(zh)
*
|
2019-06-27 |
2019-09-06 |
深圳市泛谷药业股份有限公司 |
一种安非他酮肠溶缓释微丸胶囊及其制备方法
|
AU2020344675A1
(en)
|
2019-09-13 |
2022-03-31 |
Elektrofi, Inc. |
Compositions and methods for the delivery of therapeutic biologics for treatment of disease
|
KR20220100625A
(ko)
|
2019-11-12 |
2022-07-15 |
젠자임 코포레이션 |
결핍된 cftr 활성에 의해 매개되는 질환 및 병태를 치료하기 위한 6원 헤테로아릴아미노설폰아미드
|
WO2021113809A1
(en)
|
2019-12-05 |
2021-06-10 |
Genzyme Corporation |
Arylamides and methods of use thereof
|
WO2021113806A1
(en)
|
2019-12-05 |
2021-06-10 |
Genzyme Corporation |
Arylamides and methods of use thereof
|
WO2021125800A1
(ko)
|
2019-12-16 |
2021-06-24 |
울산과학기술원 |
신생혈관형성인자의 억제를 위한 화합물 및 그 용도
|
EP4087847A4
(en)
|
2020-01-10 |
2024-02-28 |
The Regents of the University of California |
COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES
|
US20230094393A1
(en)
|
2020-02-07 |
2023-03-30 |
Elektrofi, Inc. |
Peptide particles and methods of formation
|
US20230065628A1
(en)
|
2020-02-19 |
2023-03-02 |
Elektrofi, Inc. |
Droplet Formation and Particle Morphology
|
US20230181473A1
(en)
|
2020-04-17 |
2023-06-15 |
Elektrofi, Inc. |
Methods of forming particles by continuous droplet formation and dehydration
|
KR102699528B1
(ko)
|
2020-05-05 |
2024-08-30 |
뉴베일런트, 아이엔씨. |
헤테로방향족 거대환식 에터 화학치료제
|
WO2021263072A1
(en)
|
2020-06-25 |
2021-12-30 |
Dana-Farber Cancer Institute, Inc. |
Methods of treating disease
|
US20230271918A1
(en)
|
2020-08-10 |
2023-08-31 |
Dana-Farber Cancer Institute, Inc. |
Substituted 3-amino-4-methylbenzenesulfonamides as small molecule inhibitors of ubiquitin-specific protease 28
|
AU2021326457A1
(en)
|
2020-08-10 |
2023-03-16 |
Dana-Farber Cancer Institute, Inc. |
Fused tricyclic pyrimidine-thieno-pyridine small molecule inhibitors of ubiquitin-specific protease 28
|
EP4192817A1
(en)
|
2020-08-10 |
2023-06-14 |
Dana-Farber Cancer Institute, Inc. |
Substituted 1,2,4-oxadiazoles as small molecule inhibitors of ubiquitin-specific protease 28
|
CN116323571A
(zh)
|
2020-10-23 |
2023-06-23 |
丹娜法伯癌症研究院 |
肌酸激酶(ck)的共价抑制剂以及其用于治疗和预防癌症的用途
|
AU2021390502A1
(en)
|
2020-12-01 |
2023-06-22 |
Antecip Bioventures Ii Llc |
Bupropion and dextromethorphan for reduction of suicide risk in depression patients
|
US20240058344A1
(en)
|
2020-12-18 |
2024-02-22 |
Cornell University |
Methods of treating neurodegenerative disorders and stat3-linked cancers using suppressors of electron leak
|
MX2023007450A
(es)
|
2020-12-21 |
2023-10-05 |
Univ Cornell |
Sistema de administración de fármacos ligados a péptidos.
|
WO2022150574A1
(en)
|
2021-01-08 |
2022-07-14 |
Cornell University |
Inhibitors of mycobacterium tuberculosis lipoamide dehydrogenase
|
IL306100A
(en)
|
2021-04-13 |
2023-11-01 |
Nuvalent Inc |
Amino-substituted heterocycles for the treatment of cancer with EGFR mutations
|
JP2024533216A
(ja)
|
2021-09-03 |
2024-09-12 |
ジェンザイム・コーポレーション |
インドール化合物及び使用方法
|
EP4396176A1
(en)
|
2021-09-03 |
2024-07-10 |
Genzyme Corporation |
Indole compounds and uses thereof in the treatement of cystic fibrosis
|
CN118234725A
(zh)
|
2021-10-01 |
2024-06-21 |
纽威伦特公司 |
杂芳族大环醚化合物的固体形式、药物组合物及制备
|
KR20240095536A
(ko)
|
2021-10-01 |
2024-06-25 |
뉴베일런트, 아이엔씨. |
헤테로방향족 매크로사이클릭 에테르 화합물을 사용한 고형 종양의 치료 방법
|
WO2023187422A1
(en)
|
2022-03-31 |
2023-10-05 |
Revolo Biotherapeutics Limited |
Compositions and their use in methods for treating intestinal inflammation
|
TW202400608A
(zh)
|
2022-04-07 |
2024-01-01 |
美商努法倫特公司 |
雜芳族巨環醚化合物之固體形式、醫藥組合物及製備
|
WO2023196910A1
(en)
|
2022-04-07 |
2023-10-12 |
Nuvalent, Inc |
Methods of treating solid tumor using (19r)-5-chloro-3-ethyl-16-fluoro-10,19-dimethyl-20-oxa-3,4,10,11,23-pentaazapentacyclo[19.3.1.02,6.08,12.013,18]pentacosa-1(24),2(6),4,8,11,13,15,17,21(25),22-decaen-22-amine
|
WO2023212721A1
(en)
|
2022-04-29 |
2023-11-02 |
Elektrofi, Inc. |
Injectable suspensions
|
WO2023223015A1
(en)
|
2022-05-16 |
2023-11-23 |
Revolo Biotherapeutics Limited |
Methods and compositions for preventing or treating food allergies
|
WO2023250157A1
(en)
|
2022-06-24 |
2023-12-28 |
Cornell University |
Inhibitors of mycobacterium tuberculosis lipoamide dehydrogenase
|
US11717518B1
(en)
|
2022-06-30 |
2023-08-08 |
Antecip Bioventures Ii Llc |
Bupropion dosage forms with reduced food and alcohol dosing effects
|
US12036191B1
(en)
|
2022-06-30 |
2024-07-16 |
Antecip Bioventures Ii Llc |
Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan
|
US20240277849A1
(en)
*
|
2022-06-30 |
2024-08-22 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising bupropion and cysteine
|
US11730706B1
(en)
|
2022-07-07 |
2023-08-22 |
Antecip Bioventures Ii Llc |
Treatment of depression in certain patient populations
|
US11844797B1
(en)
|
2023-04-20 |
2023-12-19 |
Antecip Bioventures Ii Llc |
Combination of dextromethorphan and bupropion for treating depression
|
WO2024013209A1
(en)
|
2022-07-13 |
2024-01-18 |
Astrazeneca Ab |
Pcsk9 inhibitors and methods of use thereof
|
WO2024036098A1
(en)
|
2022-08-12 |
2024-02-15 |
Nuvalent, Inc. |
Heteroaromatic macrocyclic ether compounds
|
WO2024036097A1
(en)
|
2022-08-12 |
2024-02-15 |
Nuvalent, Inc. |
Heteroaromatic macrocyclic ether compounds and isotopologues thereof
|
WO2024086634A1
(en)
|
2022-10-19 |
2024-04-25 |
Nuvalent, Inc. |
Heteroaromatic macrocyclic ether chemotherapeutic agents
|